Tau therapeutic strategies for the treatment of Alzheimer's disease

Current Topics in Medicinal Chemistry

Volumn 6, Issue 6, 2006, Pages 579-595

  Churcher, Ian ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Alzheimer's disease; Cdk; GSK; Kinase; MAPT; MARK; Microtubule; Tau

Indexed keywords

ALOISINE A; ALSTERPAULLONE; AMYLOID BETA PROTEIN; CASEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HYMENIALDESINE; INDIRUBIN; MALEIMIDE DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OLIGOMER; OLOMOUCINE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; ROSCOVITINE; STAUROSPORINE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AUTOPSY; DISSOCIATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE DISRUPTION; HUMAN; INHIBITION KINETICS; NERVE CELL NECROSIS; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; TAUOPATHY;

ALZHEIMER DISEASE; ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, ANIMAL; NERVE TISSUE PROTEINS; NEUROFIBRILLARY TANGLES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TAU PROTEINS;

EID: 33646198145     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776743057     Document Type: Review

References (177)

1. Buee, L.; Bussiere, T.; Buee-Scherrer, V.; Delacourte, A.; Hof, P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33, 95-130.
2. Binder, L. I.; Frankfurter, A.; Rebhun, L. I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 1985, 101, 1371-1378.
3. Kosik, K. S.; Crandall, J. E.; Mufson, E. J.; Neve, R. L. Tau in situ hybridization in normal and Alzheimer brain: localization in the somatodendritic compartment. Ann. Neurol. 1989, 26, 352-361.
4. Brady, R. M.; Zinkowski, R. P.; Binder, L., I Presence of tau in isolated nuclei from human brain. Neurobiol. Aging 1995, 16, 479-486.
5. LoPresti, P.; Szuchet, S.; Papasozomenos, S. C.; Zinkowski, R. P.; Binder, L. I. Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc. Natl. Acad. Sci. USA 1995, 92, 10369-10373.
6. Couchie, D.; Mavilia, C.; Georgieff, I. S.; Liem, R. K. H.; Shelanski, M. L.; Nunez, J. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc. Natl. Acad. Sci. USA 1992, 89, 4378-4381.
7. Weingarten, M. D.; Lockwood, A. H.; Hwo, S. Y.; Kirschner, M. W. Protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA 1975, 72, 1858-1862.
8. Khatoon, S.; Grundke-Iqbal, I.; Iqbal, K. Guanosine triphosphate binding to beta-subunit of tubulin in Alzheimer's disease brain: role of microtubule-associated protein tau. J. Neurochem. 1995, 64, 777-787.
9. Harada, A.; Oguchi, K.; Okabe, S.; Kuno, J.; Terada, S.; Ohshima, T.; Sato-Yoshitake, R.; Takel, Y.; Noda, T.; Hirokawa, N. Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature (London, United Kingdom) 1994, 369, 488-491.
10. Hwang, S. C.; Jhon, D. Y.; Bae, Y. S.; Kim, J. H.; Rhee, S. G. Activation of phospholipase C-gamma by the concerted action of tau proteins and arachidonic acid. J. Biol. Chem. 1996, 271, 18342-18349.
11. Correas, I.; Padilla, R.; Avila, J. The tubulin-binding sequence of brain microtubule-associated proteins, tau and MAP-2, is also involved in actin binding. Biochem. J. 1990, 269, 61-64.
12. Stoothoff, W. H.; Johnson, G. V. W. Tau phosphorylation: physiological and pathological consequences. Biochim. Biophys. Acta 2005, 1739, 280-297.
13. Selkoe, D. J.; Podlisny, M. B. Deciphering the genetic basis of Alzheimer's disease. Ann. Rev. Genom. Hum. Genet. 2002, 3, 67-99.
14. Lannfelt, L.; Nordstedt, C. Genetics of Alzheimer's disease - routes to the pathophysiology. J. Neural Transmission, Suppl. 2000, 59, (Advances in Dementia Research), 155-161.
15. Hardy, J.; Duff, K.; Hardy, K. G.; Perez-Tur, J.; Hutton, M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1998, 1, 355-358.
16. Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256, 184-185.
17. Coria, F.; Castano, E. M.; Frangione, B. Brain amyloid in normal aging and cerebral amyloid angiopathy is antigenically related to Alzheimer's disease beta-protein. Am. J. Pathol. 1987, 129, 422-428.
18. Levy, E.; Carman, M. D.; Fernandez-Madrid, I. J.; Power, M. D.; Liebergurg, I.; Van Duinen, S. G.; Bots, G. T. A. M.; Luyendijk, W.; Frangione, B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248, 1124-1126.
19. D'Souza, I.; Poorkaj, P.; Hong, M.; Nochlin, D.; Lee, V. M. Y.; Bird, T. D.; Schellenberg, G. D. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. USA 1999, 96, 5598-5603.
20. Grossman, M.; Farmer, J.; Leight, S.; Work, M.; Moore, P.; Van, D. V; Pratico, D.; Clark, C. M.; Coslett, H. B.; Chatterjee, A.; Gee, J.; Trojanowski, J. Q.; Lee, V. M. Y. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann. Neurol. 2005, 57, 721-729.
21. Hampel, H.; Burger, K.; Pruessner, J. C.; Zinkowski, R.; DeBernardis, J.; Kerkman, D.; Leinsinger, G.; Evans, A. C.; Davies, P.; Moller, H.; Teipel, S. J. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol. 2005, 62, 770-773.
22. Stokin, G. B.; Lillo, C.; Falzone, T. L.; Brusch, R. G.; Rockenstein, E.; Mount, S. L.; Raman, R.; Davies, P.; Masliah, E.; Williams, D. S.; Goldstein, L. S. B. Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease. Science 2005, 307, 1282-1288.
23. Feinstein, S. C.; Wilson, L. Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim. Biophys. Acta 2005, 1739, 268-279.
24. Higuchi, M.; Zhang, B.; Forman, M. S.; Yoshiyama, Y.; Trojanowski, J. Q.; Lee, V. M. Y. Axonal gegeneration induced by targeted expression of mutant human tau on oligodendrocytes of transgenic mice that model glial tauopathies. J. Neurosci. 2005, 25, 9434-9443.
25. Park, S. Y.; Ferreira, A. The generation of a 17 kDa neurotoxic fragment: An alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J. Neurosci. 2005, 25, 5365-5375.
26. Sahara, N.; Lewis, J.; DeTure, M.; McGowan, E.; Dickson, D. W.; Hutton, M.; Yen, S. H. Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J. Neurochem. 2002, 83, 1498-1508.
27. Lee, V. M. Y.; Kenyon, T. K.; Trojanowski, J. Q. Transgenic animal models of tauopathies. Biochim. Biophys. Acta 2005, 1739, 251-259.
28. Gotz, J.; Chen, F.; Van Dorpe, J.; Nitsch, R. M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293, 1491-1495.
29. Ishihara, T.; Hong, M.; Zhang, B.; Nakagawa, Y.; Lee, M. K.; Trojanowski, J. Q.; Lee, V. M. Y. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999, 24, 751-762.
30. Ishihara, T.; Zhang, B.; Higuchi, M.; Yoshiyama, Y.; Trojanowski, J. Q.; Lee, V. M. Y. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am. J. Pathol. 2001, 158, 555-562.
31. Brion, J. P.; Tremp, G.; Octave, J. N. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. Am. J. Pathol. 1999, 154, 255-270.
32. Andorfer, C.; Kress, Y.; Espinoza, M.; de Silva, R.; Tucker, K. L.; Barde, Y. A.; Duff, K.; Davies, P. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 2003, 86, 582-590.
33. Duff, K.; Knight, H.; Refolo, L. M.; Sanders, S.; Yu, X.; Picciano, M.; Malester, B.; Hutton, M.; Adamson, J.; Goedert, M.; Burki, K.; Davies, P. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol. Dis. 2000, 7, 87-98.
34. Lewis, J.; McGowan, E.; Rockwood, J.; Melrose, H.; Nacharaju, P.; Van Slegtenhorst, M.; Gwinn-Hardy, K.; Murphy, M. P.; Baker, M.; Yu, X.; Duff, K.; Hardy, J.; Corral, A.; Lin, W. L.; Yen, S. H.; Dickson, D. W.; Davies, P.; Hutton, M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 2000, 25, 402-405.
35. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274, 99-102.
36. Oddo, S.; Caccamo, A.; Shepherd, J. D.; Murphy, M. P.; Golde, T. E.; Kayed, R.; Metherate, R.; Mattson, M. P.; Akbari, Y.; LaFerla, F. M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003, 39, 409-421.
37. Oddo, S.; Caccamo, A.; Kitazawa, M.; Tseng, B. P.; LaFerla, F. M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 2003, 24, 1063-1070.
38. Morishima-Kawashima, M.; Hasegawa, M.; Takio, K.; Suzuki, M.; Yoshida, H.; Titani, K.; Ihara, Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 1995, 270, 823-829.
39. Hanger, D. P.; Betts, J. C.; Loviny, T. L. F.; Blackstock, W. P.; Anderton, B. H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 1998, 71, 2465-2476.
40. Ferrer, I.; Gomez-Isla, T.; Puig, B.; Freixes, M.; Ribe, E.; Dalfo, E.; Avila, J. Current advances on different kinases involved in Tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 2005, 2, 3-18.
41. Lee, K. Y.; Clark A. W.; Rosales, J. L.; Chapman, K.; Fung, T.; Johnston, R. N. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 1999, 34, 21-29.
42. Cruz, J. C.; Tsai, L. H. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 2004, 10, 452-458.
43. Tsai, L. H.; Lee, M. S.; Cruz, J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim. Biophys. Acta 2004, 1697, 137-142.
44. Smith, D. S.; Tsai, L. H. Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol. 2002, 12, 28-36.
45. Lee, M. S.; Kwon, Y. T.; Li, M.; Peng, J.; Friedlander, R. M.; Tsai, L. H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature (Lond) 2000, 405, 360-364.
46. Noble, W.; Olm, V.; Takata, K.; Casey, E.; O, M.; Meyerson, J.; Gaynor, K.; LaFrancois, J.; Wang, L.; Kondo, T.; Davies, P.; Burns, M.; Veeranna; Nixon, R.; Dickson, D.; Matsuoka, Y.; Ahlijanian, M.; Lau, L. F.; Duff, K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38, 555-565.
47. Cruz, J. C.; Tseng, H. C.; Goldman, J. A.; Shih, H.; Tsai, L. H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 2003, 40, 471-483.
48. Pallas, M.; Canudas, A. M.; Verdaguer, E.; Allgaier, C.; Garcia de Arriba, S.; Alvira, D.; Sureda, F. X.; Camins, A. Inhibitors of cyclin-dependent kinases: Potential drugs for the treatment of neurodegenerative disorders? Curr. Med. Chem 2005, 5, 101-109.
49. Monaco, E. A., III.; Vallano, M. L. Cyclin-dependent kinase inhibitors: Cancer killers to neuronal guardians. Curr. Med. Chem. 2003, 10, 367-379.
50. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
51. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J. P. J.; Blow, J. J.; Inagaki, N.; Inagaki, M.; Delcros, J. G.; Moulinoux, J. P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2, and cdk5. Eur. J. Biochem. 1997, 243, 527-536.
52. De Azevedo, W. F.; Leclerc, S.; Meijer, L.; Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogs. Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 1997, 243, 518-526.
53. Guzi, T. CYC-202 cyclacel. Curr. Opin. Investig. Drugs 2004, 5, 1311-1318.
54. Vita, M.; Abdel-Rehim, M.; Olofsson, S.; Hassan, Z.; Meurling, L.; Siden, A.; Siden, M.; Pettersson, T.; Hassan, M. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur. J. Pharmaceut. Sci. 2005, 25, 91-103.
55. Zhang, M.; Li, J.; Chakrabarty, P.; Bu, B.; Vincent, I. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick type C mice. Am. J. Pathol. 2004, 165, 843-853.
56. Tsai, Li Huei. Presented at "Alzheimer's Disease: From Molecular Mechanisms to Drug Discovery", Cancun 13 December 2004.
57. Vesely, J.; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella-Deana, A.; Pinna, L.; Letham, D. S.; Kato, J. Y.; Detivaud, L.; Leclerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine analogs. Eur. J. Biochem. 1994, 224, 771-786.
58. Chang, Y. T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
59. Leost, M.; Schultz, C.; Link, A.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Zaharevitz, D. W.; Gussio, R.; Senderowicz, A. M.; Sausville, E. A.; Kunick, C.; Meijer, L. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983-5994.
60. Meijer, L.; Thunnissen, A. M. W. H.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7, 51-63.
61. Kaur, G.; Stetler-Stevenson, M.; Sebers, S.; Worland, P.; Sedlacek, H.; Myers, C.; Czech, J.; Naik, R.; Sausville, E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Nat. Can. Instit. 1992, 84, 1736-1740.
62. Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.; Ceballos-Picot, I.; Noble, M.; Endicott, J.; Vierfond, J. M.; Meijer, L. Aloisines, a New Family of CDK/GSK-3 Inhibitors. SAR Study, Crystal Structure in Complex with CDK2, Enzyme Selectivity, and Cellular Effects. J. Med. Chem. 2003, 46, 222-236.
63. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J. A.; Snyder, G. L.; Greengard, P.; Biernat, J.; Wu, Y. Z.; Mandelkow, E. M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. 2001, 276, 251-260.
64. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A. L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S. M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural Basis for the Synthesis of Indirubins as Potent and Selective Inhibitors of Glycogen Synthase Kinase-3 and Cyclin-Dependent Kinases. J. Med. Chem. 2004, 47, 935-946.
65. Brachwitz, K.; Voigt B.; Meijer, L.; Lozach, O.; Schaechtele, C.; Molnar, J.; Hilgeroth, A. Evaluation of the First Cytostatically Active 1-Aza-9-oxafluorenes as Novel Selective CDK1 Inhibitors with P-Glycoprotein Modulating Properties. J. Med. Chem. 2003, 46, 876-879.
66. Voigt B.; Meijer, L.; Lozach, O.; Schaechtele, C.; Totzke, F.; Hilgeroth, A. Novel CDK inhibition profiles of structurally varied 1-aza-9-oxafluorenes. Bioorg. Med. Chem. Lett. 2005, 15, 823-825.
67. Helal, C. J.; Sanner, M. A.; Cooper, C. B.; Gant, T.; Adam, M.; Lucas, J. C.; Kang, Z.; Kupchinsky, S.; Ahlijanian, M. K.; Tate, B.; Menniti, F. S.; Kelly, K.; Peterson, M. Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg. Med. Chem. Lett. 2004, 14, 5521-5525.
68. nck5a complex. Mol. Cell 2001, 8, 657-669.
69. Mapelli, M.; Massimiliano, L.; Crovace, C.; Seeliger, M. A.; Tsai, L. H.; Meijer, L.; Musacchio, A. Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 2005, 48, 671-679.
70. Zheng, Y. L.; Kesavapany, S.; Gravell, M.; Hamilton, R. S.; Schubert, M.; Amin, N.; Albers, W.; Grant, P.; Pant, H. C. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. 2005, 24, 209-220.
71. McInnes, C.; Andrews, M. J. I.; Zheleva, D. I.; Lane, D. P.; Fischer, P. M. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr. Med. Chem. Anti-Cancer Agents 2003, 3, 57-69.
72. Battaglia, F.; Trinchese, F.; Liu, S.; Walter, S.; Nixon, R. A.; Arancio, O. Calpain inhibitors, a treatment for Alzheimer's disease: Position paper. J. Mol. Neurosci. 2003, 20, 357-362.
73. Ray, S. K.; Banik, N. L. Calpain and its involvement in the pathophysiology of CNS injuries and diseases: Therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr. Drug Targets: CNS Neurol. Disord. 2003, 2, 173-189.
74. DePetrillo, P. B. Calpain inhibitors - a review of the recent patent literature. IDrugs 2002, 5, 568-576.
75. Liu, F.; Su, Y.; Li, B.; Zhou, Y.; Ryder, J.; Gonzalez-DeWhitt, P.; May, P. C.; Ni, B. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 2003, 547, 193-196.
76. Ryder, J.; Su, Y.; Liu, F.; Li, B.; Zhou, Y.; Ni, B. Divergent roles of GSK3 and CDK5 in APP processing. Biochem. Biophys. Res. Commun. 2003, 312, 922-929.
77. Bhat, R. V.; Haeberlein, S. L. B.; Avila, J. Glycogen synthase kinase 3: A drug target for CNS therapies. J. Neurochem. 2004, 89, 1313-1317.
78. Meijer, L.; Flajolet, M.; Greengard, P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 2004, 25, 471-480.
79. Pei, J. J.; Tanaka, T.; Tung, Y. C.; Braak, E.; Iqbal, K.; Grundke-Iqbal, I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropath. Exp. Neurology 1997, 56, 70-78.
80. Jackson, G. R.; Wiedau-Pazos, M.; Sang, T. K.; Wagle, N.; Brown, C. A.; Massachi, S.; Geschwind, D. H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002, 34, 509-519.
81. Lucas, J. J.; Hernandez, F.; Gomez-Ramos, P.; Moran, M. A.; Hen, R.; Avila, J. Decreased nuclear beta-catenin, tau hyperphos-phorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001, 20, 27-39.
82. Bhat, R. V.; Shanley, J.; Correll, M. P.; Fieles, W. E.; Keith, R. A.; Scott, C. W.; Lee, C. M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad Sci. USA 2000, 97, 11074-11079.
83. Hetman, M.; Cavanaugh, J. E.; Kimelman, D.; Xia, Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 2000, 20, 2567-2574.
84. Wagner, U.; Utton, M.; Gallo, J. M.; Miner, C. C. J. Cellular phosphorylation of tau by GSK-3beta influences tau binding to microtubules and microtubule organization. J. Cell Sci. 1996, 109, 1537-1543.
85. Cho, J. H.; Johnson, G. V. W. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J. Neurochem. 2004, 88, 349-358.
86. Spittaels, K.; Van den Haute, C.; Van Dorpe, J.; Geerts, H.; Mercken, M.; Bruynseels, K.; Lasrado, R.; Vandezande, K.; Laenen, I.; Boon, T.; Van Lint, J.; Vandenheede, J.; Moechars, D.; Loos, R.; Van Leuven, F. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 2000, 275, 41340-41349.
87. Cohen, P.; Goedert, M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 2004, 3, 479-487.
88. Martinez, A.; Castro, A.; Dorronsoro, I.; Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. 2002, 22, 373-384.
89. Wagman, A. S.; Johnson, K. W.; Bussiere, D. E. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharmaceut. Des. 2004, 10, 1105-1137.
90. Kypta, R. M. GSK-3 inhibitors and their potential in the treatment of Alzheimer's disease. Exp. Opin. Therapeut. Patents 2005, 15, 1315-1331.
91. Phiel, C. J.; Klein, P. S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 789-813.
92. Shen, L.; Prouty, C.; Conway, B. R.; Westover, L.; Xu, J. Z.; Look, R. A.; Chen, X.; Beavers, M. P.; Roberts, J.; Murray, W. V.; Demarest, K. T.; Kuo, G. H. Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3b (GSK-3b) inhibitors. Bioorg. Med. Chem. 2004, 12, 1239-1255.
93. Kuo, G.-H.; Prouty, C.; DeAngelis, A.; Shen, L.; O'Neill, D.J.; Shah, C.; Connolly, P.J.; Murray, W.V.; Conway, B.R.; Cheung, P.; Westover, L.; Xu, J.Z.; Look, R.A.; Demarest, K.T.; Emanuel, S.; Middleton, S.A.; Jolliffe, L.; Beavers, M.P.; Chen, X. Synthesis and Discovery of Macrocyclic Polyoxygenates Bis-7-azaindolyl-maleimides as a Novel Series of Potent and Highly Selective Glycogen Synthase Kinase-3beta Inhibitors J. Med. Chem. 2003, 46, 4021-4031.
94. Zhang, H. C.; Ye, H.; Conway, B. R.; Derian, C. K.; Addo, M. F.; Kuo, G. H.; Hecker, L. R.; Croll, D. R.; Li, J.; Westover, L.; Xu, J. Z.; Look, R.; Demarest, K. T.; Andrade-Gordon, P.; Damiano, B. P.; Maryanoff, B. E. 3-(7-Azaindolyl)4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 2004, 14, 3245-3250.
95. O'Neill, D. J.; Shen, L.; Prouty, C.; Conway, B. R.; Westover, L.; Xu, J. Z.; Zhang, H. C.; Maryanoff, B. E.; Murray, W. V.; Demarest, K. T.; Kuo, G. H. Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg. Med. Chem. 2004, 12, 3167-3185.
96. Bertrand, J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M. Structural Characterization of the GSK-3b Active Site Using Selective and Non-selective ATP-mimetic Inhibitors. J. Mol. Biol. 2003, 333, 393-407.
97. Engler, T. A.; Malhotra, S.; Burkholder, T. P.; Henry, J. R.; Mendel, D.; Porter, W. J.; Furness, K.; Diefenbacher, C.; Marquart, A.; Reel, J. K.; Li, Y.; Clayton, J.; Cunningham, B.; McLean, J.; O'Toole, J. C.; Brozinick, J.; Hawkins, E.; Misener, E.; Briere, D.; Brier, R. A.; Wagner, J. R.; Campbell, R. M.; Anderson, B. D.; Vaughn, R.; Bennett, D. B.; Meier, T. I.; Cook, J. A. The development of potent and selective bisarylmaleimide GSK3 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 899-903.
98. Witherington, J.; Bordas, V.; Gaiba, A.; Naylor, A.; Rawlings, A. D.; Slingsby, B. P.; Smith, D. G.; Takle, A. K; Ward, R. W. 6-Heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2003, 13, 3059-3062.
99. Witherington, J.; Bordas, V.; Gaiba, A.; Garton, N. S.; Naylor, A.; Rawlings, A. D.; Slingsby, B. P.; Smith, D. G.; Takle, A. K.; Ward, R. W. 6-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2003, 13, 3055-3057.
100. Witherington, J.; Bordas, V.; Haigh, D.; Hickey, D. M. B.; Ife, R. J.; Rawlings, A. D.; Slingsby, B. P.; Smith, D. G.; Ward, R. W. 5-Aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2003, 13, 1581-1584.
101. Witherington, J.; Bordas, V.; Garland, S. L.; Hickey, D. M. B.; Ife, R. J.; Liddle, J.; Saunders, M.; Smith, D. G.; Ward, R. W. 5-Arylpyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2003, 13, 1577-1580.
102. Ring, D. B.; Johnson, K. W.; Henriksen, E. J.; Nuss, J. M.; Goff, D.; Kinnick, T. R.; Ma, S. T.; Reeder, J. W.; Samuels, I.; Slabiak, T.; Wagman, A. S.; Hammond, M. E. W.; Harrison, S. D. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, 52, 588-595.
103. Maeda, Y.; Nakano, M.; Sato, H.; Miyazaki, Y.; Schweiker, S. L.; Smith, J. L.; Truesdale, A. T. 4-Acylamino-6-arylfuro[2,3d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3907-3911.
104. Tavares, F. X.; Boucheron, J. A.; Dickerson, S. H.; Griffin, R. J.; Preugschat, F.; Thomson, S. A.; Wang, T. Y.; Zhou, H. Q. N-Phenyl4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy. J. Med. Chem. 2004, 47, 4716-4730.
105. Peat, A. J.; Boucheron, J. A.; Dickerson, S. H.; Garrido, D.; Mills, W.; Peckham, J.; Preugschat, F.; Smalley, T.; Schweiker, S. L.; Wilson, J. R.; Wang, T. Y.; Zhou, H. Q.; Thomson, S. A. Novel pyrazolopyrimidine derivatives as GSK-3 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 2121-2125.
106. Pierce, A. C.; ter Haar, E.; Binch, H. M.; Kay, D. P.; Patel, S. R.; Li, P. CH., O and CH...N Hydrogen Bonds in Ligand Design: A Novel Quinazolin-4-ylthiazol-2-ylamine Protein Kinase Inhibitor. J. Med. Chem. 2005, 48, 1278-1281.
107. Bhat, R.; Xue, Y.; Berg, S.; Hellberg, S.; Ormo, M.; Nilsson, Y.; Radesater, A.; Jerning, E.; Markgren, P.; Borgegard, T.; Nylof, M.; Gimenez-Cassina, A.; Hernandez, F.; Lucas, J. J.; Diaz-Nido, J.; Avila, J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 2003, 278, 45937-45945.
108. Noble, W.; Planel, E.; Zehr, C.; Olm, V.; Meyerson, J.; Suleman, F.; Gaynor, K.; Wang, L.; LaFrancois, J.; Feinstein, B.; Burns, M.; Krishnamurthy, P.; Wen, Y.; Bhat, R.; Lewis, J.; Dickson, D.; Duff, K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA 2005, 102, 6990-6995.
109. Phiel, C. J.; Wilson, C. A.; Lee, V. M. Y.; Klein, P. S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423, 435-439.
110. Su, Y.; Ryder, J.; Li, B.; Wu, X.; Fox, N.; Solenberg, P.; Brune, K.; Paul, S.; Zhou, Y.; Liu, F.; Ni, B. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 2004, 43, 6899-6908.
111. Pei, J. J.; Braak, H.; An, W. L.; Winblad, B.; Cowburn, R. F.; Iqbal, K.; Grundke-Iqbal, I. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Mol. Brain Res. 2002, 109, 45-55.
112. Zhu, X.; Castellani, R. J.; Takeda, A.; Nunomura, A.; Atwood, C. S.; Perry, G.; Smith, M. A. Differential activation of neuronal ERK, JNK/ SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech. Ageing Develop. 2001, 123, 39-46.
113. Pei, J. J.; Gong, C. X.; An, W. L.; Winblad, B.; Cowburn, R. F.; Grundke-Iqbal, I.; Iqbal, K. Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am. J. Pathol. 2003, 163, 845-858.
114. Rapoport, M.; Ferreira, A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J. Neurochem. 2000, 74, 125-133.
115. Li, Y.; Liu, L.; Barger, S. W.; Griffin, W. S. T. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci. 2003, 23, 1605-1611.
116. Wang, Q.; Walsh, D. M.; Rowan, M. J.; Selkoe, D. J.; Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid b-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 2004, 24, 3370-3378.
117. Lambourne, S. L.; Sellers, L. A.; Bush, T. G.; Choudhury, S. K.; Emson, P. C.; Suh, Y. H.; Wilkinson, L. S. Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: Evidence for distinct molecular processes underlying tau abnormalities. Mol. Cell. Biol. 2005, 25, 278-293.
118. Savage, M. J.; Lin, Y. G.; Ciallella, J. R.; Flood, D. G.; Scott, R. W. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J. Neurosci. 2002, 22, 3376-3385.
119. Harris, F. M.; Brecht, W. J.; Xu, Q.; Mahley, R. W.; Huang, Y. Increased tau Phosphorylation in Apolipoprotein E4 Transgenic Mice Is Associated with Activation of Extracellular Signal-regulated Kinase: Modulation by Zinc. J. Biol. Chem. 2004, 279, 44795-44801.
120. Yasojima, K.; Kuret, J.; DeMaggio, A. J.; McGeer, E.; McGeer, P. L. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Res. 2000, 865, 116-120.
121. Kuret, J.; Johnson, G. S.; Cha, D.; Christenson, E. R.; DeMaggio, A. J.; Hoekstra, M. F. Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. J. Neurochem. 1997, 69, 2506-2515.
122. Schwab, C.; DeMaggio, A. J.; Ghoshal, N.; Binder, L. I.; Kuret, J.; McGeer, P. L. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol. Aging 2000, 21, 503-510.
123. Singh, T.; Grundke-Iqbal, I.; Iqbal, K. Phosphorylation of tau protein by casein kinase-1 converts it to an abnormal Alzheimer-like state. J. Neurochem. 1995, 64, 1420-1423.
124. Li, G.; Yin, H.; Kuret, J. Casein Kinase 1 Delta Phosphorylates Tau and Disrupts Its Binding to Microtubules. J. Biol. Chem. 2004, 279, 15938-15945.
125. Sarno, S.; Ruzzene, M.; Frascella, P.; Pagano, M. A.; Meggio, F.; Zambon, A.; Mazzorana, M.; Di Maira, G.; Lucchini, V.; Pinna, L. A. Development and exploitation of CK2 inhibitors. Mol. Cell. Biochem. 2005, 274, 69-76.
126. Sarno, S.; Moro, S.; Meggio, F.; Zagotto, G.; Dal Ben, D.; Ghisellini, P.; Battistutta, R.; Zanotti, G.; Pinna, L. A. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol. Ther. 2002, 93, 159-168.
127. Litersky, J. M.; Johnson, G. V. W.; Jakes, R.; Goedert, M.; Lee, M.; Seubert, P. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem. J. 1996, 316 (Pt 2), 655-660.
128. Singh, T. J.; Grundke-Iqbal, I.; Wu, W. Q.; Chauhan, V.; Novak, M.; Kontzekova, E.; Iqbal, K. Protein kinase C and calcium/ calmodulin-dependent protein kinase II phosphorylate three-repeat and four-repeat tau isoforms at different rates. Mol. Cell. Biochem. 1997, 168, 141-148.
129. Singh, T. J.; Wang, J. Z.; Novak, M.; Kontzekova, E.; Grundke-Iqbal, I.; Iqbal, K. Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett. 1996, 387, 145-148.
130. Hasegawa, M.; Morishima-Kawashima, M.; Takio, K.; Suzuki, M.; Titani, K.; Ihara, Y. Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain. J. Biol. Chem. 1992, 267, 17047-17054.
131. Biernat, J.; Gustke, N.; Drewes, G.; Mandelkow, E. M.; Mandelkow, E. Phosphorylation of Ser262 strongly reduces binding of Tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding. Neuron 1993, 11, 153-163.
132. Nishimura, I.; Yang, Y.; Lu, B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 2004, 116, 671-682.
133. Sironi, J. J.; Yen, S. H.; Gondal, J. A.; Wu, Q.; Grundke-Iqbal, I.; Iqbal, K. Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett. 1998, 436, 471-475.
134. Bennecib, M.; Gong, C. X; Grundke-Iqbal, I.; Iqbal, K. Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. FEBS Lett. 2001, 490, 15-22.
135. Yamamoto, H.; Hiragami, Y.; Murayama, M.; Ishizuka, K.; Kawahara, M.; Takashima, A. Phosphorylation of tau at serine 416 by Ca2+/ calmodulin-dependent protein kinase II in neuronal soma in brain. J. Neurochem. 2005, 94, 1438-1447.
136. Pedersen, L. M.; Lien, G. F.; Bollerud, I.; Gjerstad, J. Induction of long-term potentiation in single nociceptive dorsal horn neurons is blocked by the CaMKII inhibitor AIP. Brain Res. 2005, 1041, 66-71.
137. Rongo, C. A fresh look at the role of CaMKII in hippocampal synaptic plasticity and memory. BioEssays 2002, 24, 223-233.
138. Lisman, J.; Schulman, H.; Cline, H. The molecular basis of CaMKII function in synaptic and behavioral memory. Nat. Rev. Neurosci. 2002, 3, 175-190.
139. Drewes, G. Marking tau for tangles and toxicity. Trends Biochem. Sci. 2004, 29, 548-555.
140. Tassan, J. P.; Le Goff, X. An overview of the KIN1/PAR-1/MARK kinase family. Biol. Cell. 2004, 96, 193-199.
141. Drewes, G.; Trinczek, B.; Illenberger, S.; Biernat, J.; Schmitt-Ulms, G.; Meyer, H. E.; Mandelkow, E. M.; Mandelkow, E. Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262. J. Biol. Chem. 1995, 270, 7679-7688.
142. Jenkins, S. M.; Johnson, G. V. W. Microtabule/MAP-affinity regulating kinase (MARK) is activated by phenylarsine oxide in situ and phosphorylates tau within its microtubule-binding domain. J. Neurochem. 2000, 74, 1463-1468.
143. Drewes, G.; Ebneth, A.; Preuss, U.; Mandelkow, E. M.; Mandelkow, E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 1997, 89, 297-308.
144. Chin, J. Y.; Knowles, R. B.; Schneider, A.; Drewes, G.; Mandelkow, E. M.; Hyman, B. T. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: A fluorescence resonance energy transfer study. J. Neuropath. Exp. Neurol. 2000, 59, 966-971.
145. Ebneth, A.; Drewes, G.; Mandelkow, E. M.; Mandelkow, E. Phosphorylation of MAP2c and MAP4 by MARK kinases leads to the destabilization of microtubules in cells. Cell Motility and the Cytoskeleton 1999, 44, 209-224.
146. Illenberger, S.; Drewes, G.; Trinczek, B.; Biernat, J.; Meyer, H. E.; Olmsted, J. B.; Mandelkow, E. M.; Mandelkow, E. Phosphorylation of microtubule-associated proteins MAP2 and MAP4 by the protein kinase p110mark. Phosphorylation sites and regulation of microtubule dynamics. J. Biol. Chem. 1996, 271, 10834-10843.
147. Schneider, A.; Biernat, J.; von Bergen, M.; Mandelkow, E.; Mandelkow, E. M. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 1999, 38, 3549-3558.
148. Mandelkow, E. M.; Thies, E.; Trinczek, B.; Biernat, J.; Mandelkow, E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J. Cell. Biol. 2004, 167, 99-110.
149. Biernat, J.; Wu, Y.; Timm, T.; Zheng-Fischhofer, Q.; Mandelkow, E.; Meijer, L.; Mandelkow, E. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol. Biol Cell. 2002, 13, 4013-4028.
150. Fortini, M. E. PAR-1 for the course of neurodegeneration. Cell 2004, 116, 631-632.
151. Peng, C. Y.; Graves, P. R.; Ogg, S.; Thoma, R. S.; Byrnes, M. J., III; Wu, Z.; Stephenson, M. T.; Piwnica-Worms, H. C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell Growth Differ. 1998, 9, 197-208.
152. Paudel, H. K. The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. J. Biol. Chem. 1997, 272, 1777-1785.
153. Correas, I; Diaz-Nido, J.; Avila, J. Microtubule-associated protein Tau is phosphorylated by protein kinase C on its tubulin binding domain. J. Biol. Chem. 1992, 267, 15721-15728.
154. Scott, C. W.; Spreen, R. C.; Herman, J. L.; Chow, F. P.; Davison, M. D.; Young, J.; Caputo, C. B. Phosphorylation of recombinant Tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly. J. Biol. Chem. 1993, 268, 1166-1173.
155. Brandt, R.; Lee, G.; Teplow, D. B.; Shalloway, D.; Abdel-Ghany, M. Differential effect of phosphorylation and substrate modulation on tau's ability to promote microtubule growth and nucleation. J. Biol. Chem. 1994, 269, 11776-11782.
156. Jicha, G. A.; Weaver, C.; Lane, E.; Vianna, C.; Kress, Y.; Rockwood, J.; Davies, P. cAMP-dependent protein kinase phosphorylations on Tau in Alzheimer's disease. J. Neurosci. 1999, 19, 7486-7494.
157. Liu, S. J.; Zhang, J. Y.; Li, H. L.; Fang, Z. Y.; Wang, Q.; Deng, H. M.; Gong, C. X.; Grundke-Iqbal, I; Iqbal, K.; Wang, J. Z. Tau Becomes a More Favorable Substrate for GSK-3 When It Is Prephosphorylated by PKA in Rat Brain. J. Biol. Chem. 2004, 279, 50078-50088.
158. Shuntoh, H.; Taniyama, K.; Fukuzaki, H.; Tanaka, C. Inhibition by cyclic AMP of phorbol ester-potentiated norepinephrine release from guinea pig brain cortical synaptosomes. J. Neurochem. 1988, 51, 1565-1572.
159. Lu, R.; Niida, H.; Nakanishi, M. Human SAD1 kinase is involved in UV-induced DNA damage checkpoint function. J. Biol. Chem. 2004, 279, 31164-31170.
160. Crump, J. G.; Zhen, M.; Jin, Y.; Bargmann, C. I. The SAD-1 kinase regulates presynaptic vesicle clustering and axon termination. Neuron 2001, 29, 115-129
161. Kishi, M.; Pan, Y. A.; Crump, J. G.; Sanes, J. R. Mammalian SAD Kinases Are Required for Neuronal Polarization. Science 2005, 307, 929-932
162. Tian, Q.; Wang, J. Role of Serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals 2002, 11, 262-269.
163. Vogelsberg-Ragaglia, V.; Schuck, T.; Trojanowski, J. Q.; Lee, V. M. Y. PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus. Exp. Neurol. 2001, 168, 402-412.
164. Gong, C. X.; Shaikh, S.; Wang, J. Z.; Zaidi, T.; Grundke-Iqbal, I.; Iqbal, K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J. Neurochem. 1995, 65, 732-738.
165. Gong, C. X.; Singh, T. J.; Grundke-Iqbal, I.; Iqbal, K. Phosphoprotein phosphatase activities in Alzheimer disease brain. J. Neurochem. 1993, 61, 921-927.
166. Gong, C. X.; Grundke-Iqbal, I.; Iqbal, K. Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 1994, 61, 765-772.
167. Ley, S. V.; Humphries, A. C.; Eick, H.; Downham, R.; Ross, A. R.; Boyce, R. J.; Pavey, J. B. J.; Pietruszka, J. Total synthesis of the protein phosphatase inhibitor okadaic acid. J. Chem. Soc. Perkin Trans.1 1998, 23, 3907-3912.
168. Forsyth, C. J.; Sabes, S. F.; Urbanek, R. A. An Efficient Total Synthesis of Okadaic Acid. J. Am. Chem. Soc. 1997, 119, 8381-8382.
169. Cohen, P. The structure and regulation of protein phosphatases. Annu. Rev. Biochem. 1989, 58, 453-508.
170. Walaas, S. I.; Greengard, P. Protein phosphorylation and neuronal function. Pharmacol. Rev. 1991, 43, 299-349.
171. Li, M.; Makkinje, A.; Damuni, Z. Molecular Identification of I1PP2A, a Novel Potent Heat-Stable Inhibitor Protein of Protein Phosphatase 2A. Biochemistry 1996, 35, 6998-7002.
172. Li, M.; Makkinje, A.; Damuni, Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J. Biol. Chem. 1996, 271, 11059-11062.
173. Tanimukai, H.; Grundke-Iqbal, I.; Iqbal, K. Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am. J. Pathol. 2005, 166, 1761-1771.
174. Tsujio, I.; Zaidi, T.; Xu, J.; Kotula, L.; Grundke-Iqbal, I.; Iqbal, K. Inhibitors of protein phosphatase-2A from human brain structures, inummocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. FEBS Lett. 2004, 579, 363-372.
175. Li, L.; Sengupta, A.; Haque, N.; Grundke-Iqbal, I.; Iqbal, K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004, 566, 261-269.
176. SantaCruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L. Ingelsson, M.; Guimaraes, A.; DeTure, M.; Ramsden, M.; McGowen, E.; Forster, C.; Yue, M.; Orne, J.; Janus, C.; Mariash, A.; Kuskowski, M.; Hymen, B.; Hutton, M.; Ashe, K. H.; Tau suppression in a Neurodegenerative Mouse Model Improves Memory Function. Science 2005, 309, 476-481.
177. Hutton, M. presented at Alzheimer's and Parkinson's Diseases: Insights, Progress and Perspectives; 7th International Conference, Sorrento, Italy, March 9-13, 2005.